Hunan Warrant Pharmaceutical (SHA:688799) received approval from China's drug administrator for the listing application of its active pharmaceutical ingredient bismuth potassium citrate.
Bismuth potassium citrate is a gastric mucosal protective agent, commonly used to treat chronic gastritis and alleviate acid-related stomach pain, according to a Monday filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 4% higher Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.